SEARCH:   Advanced

Blood, 1 July 2008, Vol. 112, No. 1, pp. 179-187. Prepublished online as a Blood First Edition Paper on February 26, 2008; DOI 10.1182/blood-2008-01-131359. This Article Full Text Full Text (PDF) Supplemental Methods and Table All Versions of this Article: blood-2008-01-131359v1 112/1/179    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Google Scholar Articles by Li, F. J. Articles by Davis, R. S. PubMed PubMed Citation Articles by Li, F. J. Articles by Davis, R. S. Related Collections Neoplasia Free Research Articles Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia Fu Jun Li1, Shouluan Ding2, Jicun Pan1, Mikhail A. Shakhmatov1, Elena Kashentseva1, Jiongru Wu1, Yufeng Li2, Seng-jaw Soong2, Nicholas Chiorazzi3,4, and Randall S. Davis1,2,5,6 1 Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham; 2 Comprehensive Cancer Center, University of Alabama at Birmingham; 3 Laboratory of Experimental Immunology, The Feinstein Institute for Medical Research, North Shore–Long Island Jewish Health System, Manhasset, NY; 4 Departments of Cell Biology and Medicine, Albert Einstein College of Medicine, Bronx, NY; 5 Department of Microbiology, University of Alabama at Birmingham; and 6 Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham CD38 and ZAP-70 are both useful prognostic markers for B-cell chronic lymphocytic leukemia (CLL), but are variably discordant with IGHV mutation status. A total of 5 human Fc receptor–like molecules (FCRL1-5) have tyrosine-based immunoregulatory potential and are expressed by B-lineage subpopulations. To determine their prognostic potential in CLL, FCRL expression was compared with IGHV mutation status, CD38 and ZAP-70 expression, and clinical features from 107 patients. FCRL1, FCRL2, FCRL3, and FCRL5 were found at markedly higher levels on CLL cells bearing mutated IGHV genes than on unmutated CLL cells or CD19+ polyclonal B lymphocytes. Univariate comparisons found that similar to CD38 and ZAP-70, FCRL expression was strongly associated with IGHV mutation status; however, only FCRL2 maintained independent predictive value by multivariate logistic analysis. Strikingly, FCRL2 demonstrated 94.4% concordance with IGHV mutation compared with 76.6% for CD38 and 80.4% for ZAP-70. Compared with other indicators, FCRL2 was also superior at predicting the time to first therapy; the median treatment-free interval was 15.5 years for patients with high FCRL2 expression compared with 3.75 years for FCRL2-low patients. Our studies indicate that FCRL2 has robust predictive value for determining IGHV gene mutation status and clinical progression and thus may further improve prognostic definition in CLL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Ligandless receptors find a role Terry J. Hamblin Blood 2008 112: 2-3. [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020